A
Abdera Therapeutics
Uses antibody engineering to design and develop new precision radiotherapeutics for cancer
About Abdera Therapeutics
Abdera Therapeutics is a biopharmaceutical company developing a new class of precision radiopharmaceuticals for cancer treatment. The company's main focus is on targeted alpha therapies (TATs), which are designed to deliver potent and highly localized radiation to tumor cells, minimizing damage to surrounding healthy tissues. Abdera's drug development platform enables the creation of therapies that can be customized to target specific proteins expressed in various types of cancer, including small cell lung cancer and other solid tumors.
The company's business model revolves around the research and development of these novel cancer therapies. Abdera Therapeutics collaborates with other companies in the biotechnology and pharmaceutical sectors to advance its drug candidates through the different stages of clinical trials. The company generates revenue through venture capital funding, partnerships, and eventually, the commercialization of its approved drugs.
Abdera Therapeutics operates in the oncology market, a rapidly growing segment of the healthcare industry. The company's target clients are patients with relapsed, refractory, and metastatic cancers, who have limited treatment options available. By developing more effective and safer cancer therapies, Abdera aims to address a significant unmet medical need and improve patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- South San Francisco, United States
- Employees
- 43
- Open positions
- None listed
- Dealroom signal
- 60.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Precision Medicine, Spinout, Biotech and Pharma, Radiotherapy, slush24, DT and LS, science-based
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Apr 2023 | $85M | $341M | Versant Ventures · venBio Partners · RTW Investments · Amplitude Ventures | ↗ |
| SERIES AOther financing | Oct 2022 | $57M | $227M | Versant Ventures · Northview LifeSciences · Amplitude Ventures | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Abdera Therapeutics is 1.8K monthly website visits, down 18.2% over the last three months. Abdera Therapeutics's team declined 42.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Northview LifeSciences
AbCellera Biologics
AdMare BioInnovations
Amplitude Ventures
Versant Ventures
venBio Partners
RTW Investments
Viking Global Investors
Qiming Venture Partners USA
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Abdera Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Abdera Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.